0001104659-26-020461
SEC filingRevenue declined 17.6% to $839M, gross margin edged up to 44.9%, but operating margin fell to 14.2%.
Axcelis Technologies, Inc. designs, manufactures and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. The ion implantation business represented 98.2% of revenue in 2025, with the remaining 1.8% derived from aftermarket sales associated with other legacy processing systems. The company also provides extensive aftermarket lifecycle products and services through its Customer Solutions & Innovation (CS&I) business, which generated $268.0 million in revenue (31.9% of total) in 2025. Axcelis has a focused strategy on ion implant and believes its Purion family of products offers the most innovative implanters on the market.
The filing does not explicitly define reporting segments. However, it distinguishes between the ion implantation business (98.2% of revenue) and aftermarket sales from other legacy processing systems (1.8% of revenue). The CS&I aftermarket business covers support for all equipment, including implanters. Systems revenue was $571.0 million in 2025, while aftermarket revenue was $268.0 million.
Axcelis offers a complete line of high energy, high current, and medium current implanters under the Purion family, including Purion H, Dragon, H200, XE, EXE, and M models. The Purion systems are based on a common platform with a single-wafer end station and advanced spot beam architectures. The company also offers the Ovation family of batch implanters, which extend the legacy GSD platform. The Purion Power Series is designed for power device applications, including silicon carbide wafers for electric vehicles. The Purion XE Power Series offers high energy capabilities for power devices.
Axcelis sells primarily through a direct sales force with offices in the United States, Taiwan, South Korea, China, Singapore, Japan, Germany, and Italy. International revenue accounted for 83.7% of total revenue in 2025, with approximately 88.6% of sales denominated in U.S. dollars. One customer accounted for 11.0% of consolidated revenues in 2025. U.S. export controls impact sales to certain Chinese customers, though the company currently ships to substantially all customers. Semiconductor Manufacturing International Corporation (SMIC) is on the Entity List but shipments are permitted under a 2020 licensing policy.
The semiconductor equipment industry is highly competitive. In ion implantation, Axcelis mainly competes against Applied Materials, the only other full-range implanter supplier. Other competitors include Sumitomo Heavy Industries, Nissin Ion Equipment (Japan), Advanced Ion Beam Technology (Taiwan), and Kingstone Semiconductor and CETC Electronics Equipment Group (China). Non-U.S. suppliers may have an advantage under U.S. export controls. In the aftermarket, there are many local competitors.
Axcelis' 2026 strategic goals include: (1) building on the long-term implant-only business model by winning customers with differentiated solutions; (2) driving profitable growth through focus on key customers and targeted markets, aiming for market share leadership; (3) increasing gross margins via upgrades, specials, and product extensions while reducing costs using Design for X and right sourcing; and (4) expanding beyond ion implant through corporate development growth initiatives. The company emphasizes R&D investment to maintain technology leadership.
As of December 31, 2025, Axcelis had 1,465 employees and 50 agency temporary staff, a 3% decrease from the prior year. Headcount is distributed with 1,038 in North America, 398 in Asia, and 79 in Europe. Voluntary turnover was 7.4% (5.0% excluding retirements), below the technology industry average of 11.7%. The company provides competitive compensation, including cash incentives tied to financial metrics, equity awards, and various benefits. Employees are required to complete at least 15 hours of training annually, with additional training available.
Revenue for 2025 was $839.0 million, a decline of 17.6% from $1,017.9 million in 2024. The decrease was driven by lower system sales, with product revenue falling 18.9% to $792.0 million. Services revenue bucked the trend, increasing 14.7% to $47.0 million. Gross margin improved modestly to 44.9% from 44.7%, as product gross margin rose 160 basis points to 47.9% due to a favorable mix of higher-margin parts and upgrades. However, services gross margin turned negative at -5.1%, compared to 5.4% in 2024, because of contract mix and expense fluctuations. Operating profit dropped to $119.3 million from $210.8 million, with operating margin compressing from 20.7% to 14.2%, largely due to higher operating expenses. Net income fell 40.2% to $120.2 million, while EPS was $3.80.
The company reports revenue in two primary segments: product (systems, spare parts, upgrades, used systems) and services (labor components). Product revenue accounted for 94.4% of total revenue (down from 96.0%), while services grew to 5.6% (up from 4.0%). In addition, management uses an alternative grouping: systems revenue was $571.0 million (down from $782.6 million), and aftermarket (CS&I) revenue rose 13.9% to $268.0 million. Aftermarket growth reflects expanding installed base and higher fab utilization. The power device segment remained key, representing 55% of system shipments. Customer concentration increased, with the top ten customers accounting for 55.2% of revenue versus 45.9% in 2024.
Management did not provide explicit revenue or earnings guidance for future periods. However, they noted capital expenditures for 2026 are projected at approximately $18 million. The company continues to invest in R&D and aftermarket services, including its 'Digital Tool Box' initiative. They highlight a strong competitive position and a focused ion implant strategy. The pending acquisition (referenced in notes) may impact near-term expenses. Liquidity remains solid with $145.5 million in cash and equivalents, no bank debt, and $228.8 million in short-term investments. Management expects existing cash and investments to satisfy anticipated requirements for the short and long term, though they acknowledge the cyclical nature of the semiconductor capital equipment industry.
As of December 31, 2025, Axcelis held $145.5M in cash and cash equivalents, $228.8M in short-term investments, and $182.4M in long-term investments, totaling $556.6M in liquid assets. Total shareholders' equity stood at $1,034.7M. The company has no traditional debt; the only debt-like obligation is a finance lease liability of $42.3M (including current portion $1.6M). Inventory increased to $329.0M from $282.2M a year earlier, reflecting a buildup of raw materials. Deferred revenue (contract liabilities) decreased to $108.9M from $138.2M, indicating lower advance payments from customers.
Purchase commitments totaled $178.0M as of year-end, primarily for inventory and other expenditures. Of this, $171.0M is expected to be paid within 2026. No other significant commitments or contingencies were noted beyond normal operating and finance leases.
During 2025, Axcelis repurchased 1.827M shares of common stock for $121.1M, significantly increasing from $60.5M in 2024. No new buyback authorization was announced in the Notes. Capital expenditures (property, plant, equipment, and capitalized software) totaled $11.3M, down from $12.2M in 2024. The company paid no dividends. Principal payments on finance lease obligations were $1.4M. There were no debt issuances or repayments.
Axcelis operates as a single reporting segment. Revenue was $839.0M in 2025, down 17.6% from $1,017.9M in 2024. Systems revenue accounted for $571.0M (68%) and aftermarket (CS&I) for $268.0M (32%). By product line, ion implantation systems and services generated $824.1M, other legacy products $15.0M. Geographically, Asia Pacific contributed $610.2M (72.7%), North America $137.1M (16.3%), and Europe $91.8M (10.9%). International revenue (including export sales from U.S. and foreign subsidiaries) was $702.0M, or 83.7% of total. Segment net income was $120.2M.
The provided excerpt from Axcelis Technologies' 10-K does not contain the actual Consolidated Statements of Cash Flows. Instead, it includes the audit report, selected notes, and a discussion of critical audit matters (systems revenue recognition and excess inventory). The only financial figure explicitly stated is total revenue of $839 million for fiscal year 2025, with $571 million from systems revenue. Without cash flow data, it is impossible to assess operational cash generation, capital expenditures, free cash flow, or capital returns. A proper analysis of cash flow quality, CFO vs. net income, capex intensity, or working capital changes cannot be performed. Users should refer to the full filing to obtain the cash flow statement figures for the years ended December 31, 2025, 2024, and 2023.